Download PDF

Fundamentals:

Ameregen is an investment portfolio of post-launch and late stage bio-engineering, nano-tech, and stem cell therapies.

Current main focus of my daily work is in international high-finance/structured finance/VC/SPV/Hedge Funds & banks. The Ameregen Group has exclusive access to assets  that are valued at $29 billion (international accounting) in cancer specialty therapeutics manufacturing, sales, marketing and distribution rights for key (non-US minded) nations, in SPVs. Monetizing these assets with exclusive launch partners in state-of-the-art advanced cancer care hospitals is current.

Ameregen is a Venture Philanthropy Corporation. The group just announced a $250,000,000.00 matching grant to go to either USC's Larry Ellison Institute of Transformational Medicine or to Stanford LPCH adding a state-of-the-art advanced cancer-rescue division where patients can self-select not to receive chemotherapies and seek cures via cell therapies.

Successful serial entrepreneur in the emergent stem cell pharmaceuticals industry. Specialties: launch team building, ultra-high-performance life science, personalized medicine, adv. cancer-rescues, intl. high-finance/structured finance, automated cGMP manufacturing of cellular therapeutics with economies of scale, high-tech/high-growth management, disruptive cancer therapeutics: R&D, immune proteomics, cellular cancer immunity,  bench-to-bedside, clinic systems. 

Supporting Media/TV/Health/Cancer-Help Channels, Public Speaker, Public Awareness  - Domain Expert on Stem Cells.

What I love about Ameregen are the people and the cutting edge, state of the art adult stem cell industry. I strongly believe in our field. Occasionally, I  make myself available as Board Member to help other stem cell companies thrive.

I lead by excellence, encouragement, and example solving challenges by win-win state-of-the-art solutions that are typically "out-of-the-box", team and patient centered, and cross-disciplinary approaches. Important to me to stay true to who I am and what I believe - please note that I believe in treating cancer without chemotherapies as there is no data that shows survival benefits since introduction of the cruel and expensive chemotherapies in the 1950s. I have seen our fully approved CITA cell therapies acutely destroy advanced stage IV, multi-drug-resistant cancers in as little as 4 hours and patients who were declared as good as dead 10 years ago are now my long-term surviving dear friends, cured. My mission in life is the 2018 roll-out of the Eradicate Cancer 2018 Project, partnering with pioneering philanthropists. Ameregen contributes the much needed CITA cancer rescue technology that is faster, cheaper, better, side-effect free.

Executive Appointments

2007Present

President & Director

AmeReGen BioPharmaceuticals Inc., SPC - A BWI Segregated Portfolio Company

Notable: AmeReGen is globally the FIRST company chartered as Venture Philanthropy, a concept Dr. Hope pioneered in corporate design creating highly efficient impact investing.

AmeReGen-ImmunoCure SP: The state-of-the-art robotic manufacturer of adult CITA stem cell products to treat cancer without side effects with cancer immune surveillance therapies.

AmeReGen Engineering & Nanotechnology SP: The exclusive turn-key manufacturer of cGMP compliant entire pharmaceutical factories that are highly automated, cost efficient, install in 1/5 of the time and for 1/5 of the cost of conventional cGMP facilities in the industry.

Swiss GI CancerHealth Tourism SP: Acquired assets of the US Cells Force Inc and CCTC Hamburg GmbH and is Swiss-patent-issued exclusive for many years to launch and treat advanced GI as well as Multi Drug Resistant (MDR+) cancers rapidly, effectively, cost-efficiently and with ease a& comfort for the patients. It's side effect free!  Currently in CH launch phase.

Ecclaisia Media SP: Productions company remarkable for its feature films in the new genre of Reality Suspense With Redemption, e media launches, TV shows & The CourageMethod®

20002007+

Var. Executive Positions General Management • CEO • CTO-US Marketing Director 

Ladera Biotech Inc; ImmunoCure Inc; VasoCure Inc; CCTC Hamburg GmbH, ZYMED

Education

20002002

General Management, Executive Management:  High-Growth Management for HiTech Companies, Advanced Marketing, Business Finance, Stanford SEP Topics 

Stanford University Graduate School of Business, GSB

Stanford Law School - Venture Capital Formation

Duke Law School - Corporate Law

19912000

M.D., Ph.D. both at: Stanford Medical University; Med Residency: Duke University

Stanford University School of Medicine & Stanford Stem Cell & Bone Marrow Transplantation, Cancer Biology and Immunology Divisions, Harvard MGH/BWH

Rigorous Medical School, MD-PhD 8-year Program. Discovery of new anti-angiogenic T-cells. Post Doc in Stem Cells, Harvard BMT (Brigham's) and MGH professional medical training.

Awards, Firsts-in-Industry & Science, Excellence

Awards for Excellence:

Life-member German Endowment for Excellence (top 0.2%), Life-member International Academy of Arts and Sciences, Direct academic work with three Nobel Laureates: Sir John Eccles, Paul Berg, PhD and Linus Pauling, PhD, Direct work with two Max-Planck Directors Jozef Schell, PhD, Georg Melchers, PhD, Direct work, study, and research with Heads of Bone Marrow Transplant, others.

Stanford "Excellence in Teaching Award", ASCO Award, ASH Award, NIH and NCI Scholar, youngest PhD student in the nation, best GPA in the nation, invented adult stem cells - re-embryonalization of differentiated cells in '88 when but a child ("wunderkind" - die ZEITmagazin'90), published in US, Jp, Korea before age 20 on stem cells, Nick named "Steve Jobs of Stem Cells", one of the three fathers of adult stem cells; inventor of cure for cancer while at Stanford - the 5th generation of stem cell and bone marrow transplantation which needs no chemo, is sheer graft-versus-tumor effect without any GvHD.

FIRST approved non-BMT stem cell therapy on the globe, CITA - in 2004.

Other firsts: Invented the concepts of venture philanthropy in 2007, invented the FIRST membrane bioreactor (JV), the FIRST drawn-vessel bioreactor, the FIRST "mail-order" cGMP facility, the FIRST mass-scalable adult stem cell mfg.

Others: PriceWaterhousCooper-Award "Start-up-for-Start-Ups" Best of Best Youngest exhibitor BIOTechnica, Ntl. Boradcasting show at age 19, inventor of several patent estates spanning stem cells, autoimmunity, nanotechnology.